Long-term results for dupilumab are very promising!
Reviewed by Joanna Stephens

Eosinophilic chronic rhinosinusitis (eCRS) is complicated by frequent early and aggressive recurrence of polyps after both medical and surgical treatment regimes. Dupilumab is an anti-IL-4/IL-3 receptor monoclonal antibody and has been previously studied in the SINUS-52 study, with an observation period of one year, which showed promising results in both symptom scores and olfactory testing. This study looks at the ongoing results beyond one year, in terms of nasal polyp score, CT scoring and olfactory testing. The findings suggest that the long-term effects of dupilumab are even more promising than the short term, with an improvement in olfactory test scores later in the evaluation, which is statistically significant – more so than in the earlier evaluation. Nasal polyp score improved, and the results were longstanding and reached statistical significance. In terms of olfactory cleft appearances on CT, the short-term results showed little change but the long-term assessment confirmed a statistically significant improvement. In summary, dupilumab was shown to have long-term efficacy in treating CRS symptoms and improving appearances on CT and nasal polyps score. Interestingly, the longer the treatment was continued for, the better the results and both olfaction and olfactory cleft appearances (clearly inextricably linked) show this benefit. It is becoming clear that dupilumab will now become an alternative treatment option to systemic corticosteroids for refractory CRS.

Long-term efficacy of Dupilumab for Eosinophilic Chronis Rhinosinusitis.
Tsunemi Y, Nakayama T, Kashiwagi T, et al.
AM J RHINOL ALLERGY
2024;38(1):14–22.